Skip to content

Genetics of Insulin and Incretins in Cystic Fibrosis

Evaluation of the Enteroinsular Axis in Cystic Fibrosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01852448
Enrollment
550
Registered
2013-05-13
Start date
2013-05-01
Completion date
2027-07-01
Last updated
2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Brief summary

Cystic fibrosis related diabetes (CFRD) is associated with worse CF-relevant outcomes. The mechanisms underlying CFRD development are not fully understood, but recent evidence suggests Type 2 Diabetes Mellitus (T2DM) mechanisms may be involved and may involve incretins (gut secreted hormones that augment insulin secretion in response to a nutrient load). This study will examine the prevalence of Genome wide association study (GWAS)-implicated T2DM alleles (including TCF7L2) across the spectrum of glucose abnormalities in CF and will use this information to compare incretin and insulin secretion in non-diabetic children and adults with high risk and low risk alleles.

Detailed description

CFRD is associated with worse nutritional status, greater pulmonary function decline, and increased mortality, highlighting its relevance in CF and arises primarily from compromised insulin secretion--traditionally considered a by-product of pancreatic exocrine tissue damage and fibrosis. Recent developments in the field of diabetes are propelling a re-examination of this basic explanation. Genome-wide association studies have associated genetic variants in TCF7L2, a transcription factor implicated in enteroendocrine function, with increased susceptibility to T2DM and CFRD. The Objectives of this study are to perform targeted sequencing of TCF7L2 and other GWAS-associated T2DM genes in the pediatric and adult CF populations and then to compare insulin secretory capacity, β-cell sensitivity to glucose, and incretin secretion in non-diabetic CF subjects with high and low-risk alleles. Phase 1 will include 450-500 subjects (Children age\>= 2 years, adolescents, and adults) for TCF7L2 genotype and ten other GWAS-implicated T2DM genes. The distribution of TCF7L2 and other GWAS-implicated T2 DM genes across the spectrum of glucose abnormalities will be described. Phase 1 requires a single blood or saliva sample and review of medical records.

Interventions

A blood or saliva sample will be obtained for genotyping of TCF7L2 and approximately ten other genes implicated in type 2 diabetes.

Sponsors

Children's Hospital of Philadelphia
Lead SponsorOTHER
University of Pennsylvania
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Subjects age \>2y 2. Diagnosis of Cystic Fibrosis 3. For subjects\< 18 years, parental/guardian permission (informed consent) and if appropriate, child assent

Exclusion criteria

1. Established diagnosis of non-CFRD (cystic fibrosis related diabetes) (e.g T1DM) .

Design outcomes

Primary

MeasureTime frameDescription
Blood sample for DNA to genotype TCF7L2 and about 10 other GWAS-implicated T2DM genes.1 dayTo examine the prevalence of GWAS-implicated T2DM alleles (including TCF7L2) across the spectrum of glucose abnormalities in children and adults with CF.

Countries

United States

Contacts

CONTACTRachel Walega
walegar1@chop.edu267-586-5969
PRINCIPAL_INVESTIGATORAndrea Kelly, MD

Children's Hospital of Philadelphia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026